Transforming growth factor β1 stimulates urokinase plasminogen activator system on prostate cancer cells

International Journal of Biological Markers

Volumn 18, Issue 2, 2003, Pages 147-151

  Ünlü, Ali ^a   Leake, R E ^b  

^a MERSIN UNIVERSITY   (Turkey)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Plasminogen inhibitor; Prostate; Transforming growth factor beta; Urokinase plasminogen acitivator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE; TGFB1 PROTEIN, HUMAN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER INVASION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; CELL CULTURE; CELL DIVISION; CHEMISTRY; DRUG EFFECT; MALE; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

CELL DIVISION; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROSTATIC NEOPLASMS; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0042199143     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/jbm.2008.2043     Document Type: Article

References (24)

1. Moses HL, Yang EY, Pietenpol JA. TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 1990; 63: 245-7.
2. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
3. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor β. J Cell Biol 1986; 103: 2403-10.
4. Atfi A, Samperez S. Secretion of transforming growth factor-β by immature rat prostate. Prostate 1994; 24: 149-155.
5. Steiner MS. Role of peptide growth factors in the prostate: A review. Urology 1993; 42: 99-110.
6. Martikainen F, Kyprianu N, Isaacs JT. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells. Endocrinology 1990; 127: 2963-8.
7. Steiner M, Zhou ZZ, Tonb DC, Barrack ER. Expression of transforming growth factor β1 in prostate cancer. Endocrinology 1994; 135: 2240-7.
8. Sehgal I, Baley PA, Thompson TC. Transforming growth factor β1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996; 56: 3359-65.
9. Carruba G, Leake RE, Rinaldi F, et al. Steroid-growth factor interaction in human prostate cancer. 1. Short term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 1994; 59: 412-20.
10. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995; 61: 597-600.
11. Ganesh S, Sier CF, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 48: 4065-71.
12. Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5.
13. Schmitt M, Janicke F. Tumour-associated urokinase-type plasminogen activator: Biological and clinical significance. Biol Chem Hoppe-Seyler 1992; 373: 611-22.
14. Billstrom A, Lecander I, Dagnaes-Hansen F, Dahllof B, Stenram U, Hartley-Asp B. Differential expression of uPA in an aggressive (DU145) and a nonaggressive (1013L) human prostate cancer xenograft. Prostate 1995; 26: 94-104.
15. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
16. de Witte JH, Sweep CG, Klijn JG, et al. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br J Cancer 1999; 79: 1190-8.
17. Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM. Plasminogen activators in human prostate cancer cell lines and tumors: Correlation with the aggressive phenotype. J Urology 1989; 142: 193-8.
18. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47: 3239-45.
19. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell End 1989; 62: 79-87.
20. Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001; 34: 347-52.
21. Zeilhofer HE, Bock KP, Dettmar P, et al. Oral squamous cell carcinoma (OSCC) - the role of the tumor associated proteases uPA, PAI-1, cathepsin D, cathepsin B, cathepsin L and the receptor uPA-R. Eur J Cancer 1997; 33: S184.
22. Janicke F, Schimtt M, Graef H. Clinical relevance of the urokinase type and tissue plasminogen activators and of their type-1 inhibitor in breast cancer. Semin Thromb Hemost 1991; 17:303-12.
23. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EKO, Medcalf RL, Sordat B. Plasminogen-activator inhibitor type-1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci 1990; 87: 6939-43.
24. Festuccia C, Angelucci A, Gravina GL, et al. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer 2000; 85: 407-15.